Clinical Trial

Varenicline OTC Trial on Efficacy and Safety

Study Description

Varenicline OTC Trial on Efficacy and Safety

The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - 1.0mg Varenicline b.i.d.

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.

Drug - 0.5mg Varenicline b.i.d.

Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.

Drug - 0.0mg placebo Varenicline b.i.d.

Product that looks like active varenicline, but contains no active ingredient

Additional Information

Official Study Title

Varenicline OTC Trial on Efficacy and Safety

Clinical Trial ID

NCT03557294

ParticipAid ID

PdyQnd